Patients with EGFR mutations and ALK gene rearrangements are known to have poor responses to immunotherapy and have been excluded from recent immunotherapy trials.30 PDL‐1 expression and tumor mutation burden31 are known biomarkers for predicting response to immunotherapy. Here, EGFR is linked to neoplasm.